11 completed, 2 recruiting, 2 unknown, 1 terminated. 3 Phase 2, 3 Phase 3, 2 Phase 4, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 3 | Completed 3 |
| Phase 4 | 2 | Completed 2 |
| Early Phase 1 | 1 | Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Hemosiderosis: new trials by email Literature Review of Hemosiderosis trials Research Report on Hemosiderosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation. Cohort - Iron Overload, Hemosiderosis | Recruiting | Assistance Publique - Hôpitaux de Paris | 500 | 2025-08-20 | 2026-04-27 | |
| Infectious and Non-infectious Lower Respiratory Diseases in Children With Down Syndrome Followed in Pediatric Pulmonology Consultations in Ile-de-France lower respiratory tract disease - Down Syndrome | Completed | Centre Hospitalier Sud Francilien | 108 | 2024-03-28 | 2024-08-15 | |
| Leflunomide for Idiopathic Pulmonary Hemosiderosis in Children Leflunomide, Steroid Drug - Idiopathic Pulmonary Hemosiderosis, Leflunomide | Phase 1 / Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 34 | 2023-06-01 | 2023-07-10 |
| Efficacy of Bone Marrow Mesenchymal Stem Cell in Pulmonary Hemosiderosis Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis - Idiopathic Pulmonary Hemosiderosis | Early Phase 1 | Unknown | Sun Yat-sen University | 100 | 2017-01-01 | 2016-12-07 |
| The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Patients Steatohepatitis, Nonalcoholic, Hemosiderosis | Terminated | The Geneva Foundation | 150 | 2016-02-10 | 2023-02-24 | |
| Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content MRI - Iron Overload, Hemochromatosis | Completed | University of Wisconsin, Madison | 207 | 2015-08-12 | 2025-08-12 | |
| A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients. Thalassemia, Brain Function (Measured by ERP Level) | Unknown | HaEmek Medical Center, Israel | 120 | 2013-09-01 | 2019-10-31 | |
| Non-invasive Quantification of Liver Iron With MRI Non-contrast MRI - Iron Overload, Hemosiderosis | Completed | University of Wisconsin, Madison | 50 | 2012-01-01 | 2019-12-06 | |
| Pharmacogenetic Study in Patients Received Iron Chelating Agent Hemosiderosis | Completed | Seoul National University Hospital | 100 | 2007-12-01 | 2014-07-14 | |
| Safety, Tolerability, and Efficacy of Deferasirox in MDS Deferasirox - Myelodysplastic Syndromes, Hemosiderosis | Phase 3 | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 158 | 2007-06-01 | 2016-11-22 |
| Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) Deferasirox - Beta-thalassemia Major, Hemosiderosis | Phase 4 | Completed | Novartis Pharmaceuticals | 233 | 2005-06-01 | 2011-08-31 |
| A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis deferasirox - Beta-Thalassemia, Hemosiderosis | Phase 3 | Completed | Novartis | 252 | 2004-05-01 | 2017-03-01 |
| Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients Deferasirox - Anemia, Hemosiderosis | Phase 2 | Completed | Novartis Pharmaceuticals | 184 | 2004-03-01 | 2011-05-09 |
| Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions ICL670, deferoxamine - Beta-Thalassemia | Phase 3 | Completed | Novartis Pharmaceuticals | 595 | 2003-05-01 | 2012-04-19 |
| Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions ICL670, deferoxamine - Anemia, Sickle Cell | Phase 2 | Completed | Novartis Pharmaceuticals | 195 | 2003-05-01 | 2017-08-22 |
| Efficacy Study in Removing Excess Iron From the Heart Ferriprox (deferiprone), Desferal (deferoxamine) - Thalassemia Major, Hemosiderosis | Phase 4 | Completed | ApoPharma | 60 | 2002-12-01 | 2016-01-05 |
Iron Overload (8) · Thalassemia (4) · beta-Thalassemia (4) · Hemochromatosis (2) · Hemosiderosis, Pulmonary (2) · Anemia (1) · Anemia, Sickle Cell (1) · Asthma (1) · Bronchiolitis (1) · Down Syndrome (1) · Fatty Liver (1) · Graft vs Host Disease (1) · Liver Cirrhosis (1) · Liver Diseases (1)
Iron Metabolism Disorders (16) · Metabolic Diseases (16) · Nutritional and Metabolic Diseases (16) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Genetic Diseases, Inborn (8) · Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Iron Overload (8) · Anemia (6) · Anemia, Hemolytic (6) · Anemia, Hemolytic, Congenital (6) · Hemoglobinopathies (6) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Digestive System Diseases (2)
Deferasirox (6) · Deferoxamine (3) · Cohort Studies (1) · Deferiprone (1) · Leflunomide (1) · Magnetic Resonance Imaging (1)
Novartis Pharmaceuticals (4) · University of Wisconsin, Madison (2) · ApoPharma (1) · Assistance Publique - Hôpitaux de Paris (1) · Centre Hospitalier Sud Francilien (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · HaEmek Medical Center, Israel (1) · Novartis (1) · Seoul National University Hospital (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Sun Yat-sen University (1) · The Geneva Foundation (1)
United States (6) · France (3) · Italy (3) · Egypt (2) · Lebanon (2) · Oman (2) · Saudi Arabia (2) · Syria (2) · Belgium (1) · Canada (1) · China (1) · Germany (1) · Greece (1) · Israel (1) · South Korea (1)
Ali Taher, Ass.Prof. (1) · Antonio Piga, M.D. (1) · Carina Levin, MD (1) · Christian Carlosn, MD (1) · Markissia Karagiorga, M.D. (1) · Renzo Galanello, M.D. (1) · Scott B Reeder, MD, PhD (1) · Scott Reeder (1) · Vassilis Ladis, M.D. (1)
PMID 15615854, PMID 15891110, PMID 17233848, PMID 17951527, PMID 19721001, PMID 20424435, PMID 21128750, PMID 21585237, PMID 23154940, PMID 23801540, PMID 25199788, PMID 25204541, PMID 27405703, PMID 36194113, PMID 37975597, PMID 39238238
R01DK100651 (1)